Elicio Therapeutics 株価情報 (NASDAQ: ELTX)

Elicio Therapeutics (NASDAQ:ELTX) 株価情報

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Elicio Therapeutics Inc

Riverview Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSB#NASDAQ">RVSB</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 25 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $12.90 million which beat the analyst consensus estimate of $12.40 million by 4.03 percent. This is a 42.60 percent increase over sales of $9.05 million the same period last year.

Earnings

Earnings Beats

News

RVSB

Riverview Bancorp Q4 EPS $0.05 Beats $0.03 Estimate, Sales $12.90M Beat $12.40M Estimate

Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are tanking in Tuesday&#8217;s after-hours session after the company reported preliminary results for its <a href="https://www.benzinga.com/pressreleases/25/04/b45084091/supermicro-provides-third-quarter-fiscal-2025-business-update-and-preliminary-financial-results">fiscal third quarter</a>.
What Happened: Super Micro reported weak preliminary results for the third quarter after market close, citing delayed customer platform decisions that moved sales into the fourth quarter.
The company now expects to report third-quarter revenue of $4.5 billion to $4.6 billion, down from prior guidance of $5 billion to $6 billion. Super Micro also expects third-quarter adjusted earnings to be in the range of 29 cents to 31 cents per share, down from prior guidance of 46 cents to 62 cents per share. 
Super Micro further noted that GAAP and non-GAAP gross margin for the third quarter was 220 basis points lower than the second quarter, primarily due to &#8220;higher inventory reserves resulting from older generation products and expedite costs to enable time-to-market for new products.&#8221;
One bright spot from the release is that new generation product designs were &#8220;robust,&#8221; the company said.
Super Micro will report audited results for the <a href="https://www.benzinga.com/calendars/earnings">third quarter</a> after the market close on May 6. Company executives will further discuss the shortfall on a conference call scheduled for 5 p.m. ET that day. 
<a href="http://benzinga.com/quote/smci">Super Micro Computer shares</a> were down 16.64% after hours, trading at $30.05 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Other chip companies were facing selling pressure following the preliminary release, including NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), down 1.84%; Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), down 1.86% and Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>), down 4.87% at $89.21 for after-hours Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/45033025/nvidia-faces-new-challenge-as-huawei-tests-powerful-ascend-910d-ai-chip-amid-us-sanctions-aiming-to-disrupt-high-end-market-report">Nvidia Faces New Challenge As Huawei Tests Powerful Ascend 910D AI Chip Amid US Sanctions, Aiming To Disrupt High-End Market: Report</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/jackpress">jackpress</a>/Shutterstock.

Guidance

After-Hours Center

Movers

Tech

DELL

NVDA

SMCI

Super Micro Computer Stock Is Tanking After Hours: What's Fueling The Sell-Off?

Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) reported its first quarter 2025 results on Tuesday.
Polaris <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45061142/polaris-inc-first-quarter-2025-financial-results-available-on-companys-website" rel="noreferrer noopener">reported </a>a first-quarter adjusted loss of 90 cents per share, beating the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">street view of 91 cents loss</a>. Quarterly sales of $1.54 billion (down 12% year over year) were in line with the analyst consensus estimate.
Primary factors affecting first-quarter sales were lower volume due to planned shipment reductions and lower net pricing driven by higher promotional spend.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44876406/retail-slowdown-and-tariff-turbulence-hit-leisure-stocks-says-analyst" rel="noreferrer noopener">Retail Slowdown, Tariffs Jolt Leisure Stocks: Analyst Revises Estimates For Topgolf, Harley-Davidson And More</a>
North America sales of $1.290 billion (down 11% year over year) represented 84 percent of total sales. International sales of $246 million (down 16% year over year) represented 16% of total sales.
&#8220;While consumer uncertainty and a dynamic tariff environment are near-term hurdles, we are thoughtfully navigating these challenges,&#8221; said Mike Speetzen, Chief Executive Officer of Polaris. However, the company noted minimal first-quarter tariff impact due to timing.
The adjusted gross profit margin of 16.6% decreased by 242 basis points, primarily due to higher promotional activity and negative foreign exchange.
Operating expenses were $303 million in the first quarter of 2025 compared to $313 million in the year-ago period.
Polaris exited the quarter with cash and equivalents worth $291.7 million and inventories of $1.748 billion.
Outlook: The company introduced second-quarter 2025 sales guidance of $1.6 billion to $1.8 billion versus the $1.820 billion estimate.
Polaris said it is withdrawing the full-year 2025 guidance due to trade and economic uncertainty.
Price Action: PII shares traded higher by 0.27% to $33.83&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45059922/uber-orders-employees-back-to-office-three-days-a-week-good-is-not-going-to-be-good-enough-ceo-says" target="_blank" rel="noreferrer noopener">Uber Orders Employees Back To Office 3 Days A Week: Good &#8216;Is Not Going To Be Good Enough,&#8217; Says CEO Dara Khosrowshahi</a></li>
</ul>
Photo by Steve Skjold via Shutterstock

Equities

Markets

General

Polaris Q1 Sales Fall, CEO Warns Of 'Consumer Uncertainty' And 'Dynamic Tariff Environment' As Near-term Hurdles

<a href="https://api.mziq.com/mzfilemanager/v2/d/83a9acb7-4ada-4a58-97e4-257b49aec76b/4f84edfe-08f2-6818-e184-5a691b3f6cd8?origin=1">https://api.mziq.com/mzfilemanager/v2/d/83a9acb7-4ada-4a58-97e4-257b49aec76b/4f84edfe-08f2-6818-e184-5a691b3f6cd8?origin=1</a>

Trump Media & Technology Publishes Letter to Shareholders; Says Looking Ahead, Assessing Various Means Of Monetizing Truth+ Platform; Says In Near Future, Plans To Offer Premium Features On Truth Social Platform To Subscribers Of Truth+ Streaming Service

<h3>Gainers</h3>
<ul>
<li>Magic Empire Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEGL#NASDAQ">MEGL</a>) shares rose 11.3% to $1.4 during Tuesday's after-market session. The company's market cap stands at $5.7 million. </li>
<li>Patriot Ntl Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNBK#NASDAQ">PNBK</a>) stock rose 8.9% to $4.28. The company's market cap stands at $315.5 million. </li>
<li>Maiden Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHLD#NASDAQ">MHLD</a>) stock increased by 7.25% to $1.33. The market value of their outstanding shares is at $132.3 million. </li>
<li>Future FinTech Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTFT#NASDAQ">FTFT</a>) shares moved upwards by 5.81% to $1.6. The market value of their outstanding shares is at $4.8 million. </li>
<li>Advanced Flower Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) shares moved upwards by 4.88% to $5.58. The market value of their outstanding shares is at $126.0 million. </li>
<li>ACRES Commercial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACR#NYSE">ACR</a>) stock rose 4.59% to $20.04. The company's market cap stands at $148.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Prestige Wealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWM#NASDAQ">PWM</a>) shares declined by 9.1% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $12.4 million. </li>
<li>Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) shares decreased by 8.54% to $72.48. The company's market cap stands at $12.8 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) shares fell 7.16% to $8.3. The market value of their outstanding shares is at $334.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>Powell Max (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) stock decreased by 6.42% to $0.38. The company's market cap stands at $5.5 million. The company's, FY earnings came out yesterday. </li>
<li>LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) shares declined by 6.09% to $10.34. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Triller Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILLR#NASDAQ">ILLR</a>) shares declined by 4.73% to $1.31. The company's market cap stands at $198.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFCG

FTFT

HRZN

ILLR

MEGL

MHLD

PMAX

PNBK

12 Financials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares rose 26.8% to $1.8 during Tuesday's after-market session. The company's market cap stands at $7.8 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock moved upwards by 17.85% to $0.2. The company's market cap stands at $5.1 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares moved upwards by 9.09% to $0.51. The company's market cap stands at $24.8 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock rose 9.03% to $0.59. The company's market cap stands at $3.5 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) stock rose 7.69% to $4.2. The market value of their outstanding shares is at $32.6 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares rose 7.29% to $0.44. The company's market cap stands at $4.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined by 17.7% to $0.25 during Tuesday's after-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Akari Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) shares decreased by 16.43% to $1.17. The company's market cap stands at $33.7 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 8.38% to $0.2. The market value of their outstanding shares is at $1.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock decreased by 7.66% to $0.24. The company's market cap stands at $12.5 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 7.55% to $2.82. The market value of their outstanding shares is at $12.9 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock declined by 7.37% to $0.02. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

AKTX

ASBP

BCDA

CYCC

GCTK

LGMK

MNDR

NCNA

PTIX

RADX

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Kforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) shares moved upwards by 31.2% to $48.0 during Tuesday's after-market session. The market value of their outstanding shares is at $917.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares moved upwards by 22.33% to $1.26. The market value of their outstanding shares is at $21.8 million. </li>
<li>Global Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) shares increased by 11.22% to $24.68. The company's market cap stands at $946.7 million. The company's, Q1 earnings came out today. </li>
<li>Orion Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) shares rose 10.58% to $7.0. The company's market cap stands at $272.9 million. As per the press release, Q1 earnings came out today. </li>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) shares increased by 8.76% to $0.87. The company's market cap stands at $5.2 million. </li>
<li>Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) shares rose 5.68% to $0.29. The market value of their outstanding shares is at $8.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AirJoule Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) shares fell 9.3% to $4.6 during Tuesday's after-market session. The market value of their outstanding shares is at $259.6 million. </li>
<li>Wabash National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) stock decreased by 9.24% to $9.04. The company's market cap stands at $382.2 million. </li>
<li>Vicor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) shares declined by 8.96% to $47.26. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares decreased by 5.23% to $0.92. The company's market cap stands at $333.8 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) shares declined by 4.74% to $26.35. The company's market cap stands at $1.6 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Sentage Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTG#NASDAQ">SNTG</a>) stock fell 4.74% to $1.61. The company's market cap stands at $4.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRJ

ATXG

KFRC

SNTG

VICR

WATT

WERN

ZBAI

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) stock rose 21.2% to $0.26 during Tuesday's after-market session. The company's market cap stands at $23.7 million. </li>
<li>Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) shares rose 11.57% to $16.0. The company's market cap stands at $4.7 billion. The company's, Q1 earnings came out today. </li>
<li>E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) shares increased by 9.52% to $2.3. The company's market cap stands at $711.4 million. As per the news, the Q4 earnings report came out today. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares increased by 8.96% to $0.67. The company's market cap stands at $2.1 million. </li>
<li>Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) stock moved upwards by 8.21% to $67.76. The market value of their outstanding shares is at $6.3 billion. The company's, Q4 earnings came out today. </li>
<li>Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) stock moved upwards by 7.84% to $88.0. The market value of their outstanding shares is at $18.6 billion. As per the press release, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares decreased by 16.4% to $30.09 during Tuesday's after-market session. The market value of their outstanding shares is at $17.9 billion. </li>
<li>Ribbon Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) shares fell 12.5% to $3.29. The company's market cap stands at $578.8 million. The company's, Q1 earnings came out today. </li>
<li>Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) shares fell 10.93% to $30.0. The market value of their outstanding shares is at $3.6 billion. As per the press release, Q1 earnings came out today. </li>
<li>First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares declined by 9.16% to $124.67. The company's market cap stands at $13.3 billion. As per the press release, Q1 earnings came out today. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares declined by 6.95% to $0.25. The company's market cap stands at $17.3 million. </li>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock decreased by 6.47% to $0.42. The market value of their outstanding shares is at $26.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

ETWO

FRSH

FSLR

GRYP

MRIN

NVNI

QRVO

RBBN

TENB

12 Information Technology Stocks Moving In Tuesday's After-Market Session

CTKB

Cytek Biosciences Showcases Its Patented Full Spectrum Profiling Technology at CYTO and IMMUNOLOGY2025

Primis Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.25 by 44 percent. This is a 46.15 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $34.12 million which beat the analyst consensus estimate of $26.88 million by 26.93 percent. This is a 20.42 percent decrease over sales of $42.87 million the same period last year.

Earnings Misses

FRST

Primis Finl Q1 Adj. EPS $0.14 Misses $0.25 Estimate, Sales $34.12M Beat $26.88M Estimate

Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) is looking for Q2 Adj EPS of $2.10-$2.40 vs $2.26 analyst estimate. sees sales of $565.000 million-$595.000 million vs $579.56 million analyst estimate.

LFUS

Littelfuse Sees Q2 Adj EPS $2.10-$2.40 vs $2.26 Est; Sees Sales $565.000M-$595.000M vs $579.56M Est

Qorvo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) released its fourth-quarter results after Tuesday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/g45082146/qorvo-announces-fiscal-2025-fourth-quarter-financial-results"> from the report. </a>
The Details: Qorvo reported quarterly earnings of $1.42 per share, which beat the analyst consensus estimate of $1.00 by 42%. Quarterly revenue clocked in at $869.5 million, beating the consensus estimate of $850.39 million.
Read Next: <a href="https://www.benzinga.com/news/legal/25/04/45056354/alexandria-ocasio-cortez-askshow-much-did-majorie-taylor-greene-make-when-she-bought-the-dip?utm_source=articleShare">Alexandria Ocasio-Cortez Asks,&#8217;How Much Did Majorie Taylor Greene Make When She Bought The Dip?&#8217;</a>
&#8220;During the March quarter, Qorvo achieved stronger than seasonal sequential revenue while surpassing the midpoint of EPS guidance by 42 cents and expanding gross margin year-over-year. Looking across our business segments, our growth and margin targets are anchored in a multi-year strategy focused on winning content with our largest customer and building on our core RF and power expertise to drive diversification through CSG and HPA,&#8221; Bob Bruggeworth, CEO of Qorvo, said.
Outlook:&nbsp;Qorvo is looking for&nbsp;first-quarter adjusted earnings of between 50 cents and 75 cents per share, versus the 59 cent estimate, and revenue in a range of $750 million to $800 million, versus the $756.37 million analyst estimate. 
QRVO Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Qorvo stock was up 10.14% after-hours at $69 on Tuesday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/45076599/sell-in-may-and-go-away-only-in-bear-markets-one-expert-says?utm_source=articleShare">&#8216;Sell In May And Go Away?&#8217; Only In Bear Markets, One Expert Says&nbsp;</a></li>
</ul>
Photo: Shutterstock

Qorvo Stock Rallies After Solid Q4 Results, Strong Q1 Guidance

Rehlko Enters Exclusive Deal with Toyota to Provide Fuel Cell Modules

Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Medallion Finl to report an earnings per share (EPS) of $0.32.
The announcement from Medallion Finl is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.10 in the last quarter, leading to a 7.22% increase in the share price on the following day.
Here's a look at Medallion Finl's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.33</td>
<td>0.37</td>
<td>0.35</td>
<td>0.36</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.43</td>
<td>0.37</td>
<td>0.30</td>
<td>0.42</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745960524_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Medallion Finl were trading at $8.76 as of April 28. Over the last 52-week period, shares are up 14.05%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/MFIN/earnings">To track all earnings releases for Medallion Finl visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MFIN

Uncovering Potential: Medallion Finl's Earnings Preview

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Accuray to report an earnings per share (EPS) of $-0.05.
Accuray bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.06, leading to a 8.03% increase in the share price on the subsequent day.
Here's a look at Accuray's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.04</td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.02</td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>3.0%</td>
<td>52.0%</td>
<td>-28.999999999999996%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745960506_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Accuray were trading at $1.61 as of April 28. Over the last 52-week period, shares are down 25.35%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ARAY/earnings">To track all earnings releases for Accuray visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAY

Insights Ahead: Accuray's Quarterly Earnings

Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) reported quarterly earnings of $2.19 per share which beat the analyst consensus estimate of $1.81 by 20.99 percent. This is a 24.43 percent increase over earnings of $1.76 per share from the same period last year. The company reported quarterly sales of $554.31 million which beat the analyst consensus estimate of $540.14 million by 2.62 percent. This is a 3.53 percent increase over sales of $535.38 million the same period last year.

Littelfuse Q1 Adj. EPS $2.19 Beats $1.81 Estimate, Sales $554.31M Beat $540.14M Estimate

Ratings for Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $253.75, along with a high estimate of $265.00 and a low estimate of $242.00. Witnessing a positive shift, the current average has risen by 5.12% from the previous average price target of $241.38.
<img src="https://www.benzinga.com/files/images/story/2025/1745960484_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cheniere Energy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean Ann Salisbury</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$258.00</td>
<td>$254.00</td>
</tr>
<tr>
<td>Brandon Bingham</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$242.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$247.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Robert Mosca</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$254.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Brandon Bingham</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$254.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$255.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Fotis Giannakoulis</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cheniere Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cheniere Energy compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Cheniere Energy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cheniere Energy's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LNG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cheniere Energy analyst ratings.</a>
<h2>All You Need to Know About Cheniere Energy</h2>
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
<h3>A Deep Dive into Cheniere Energy's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Cheniere Energy's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -8.02%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Cheniere Energy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.02% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Cheniere Energy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 18.09%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cheniere Energy's ROA stands out, surpassing industry averages. With an impressive ROA of 2.25%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Cheniere Energy's debt-to-equity ratio is notably higher than the industry average. With a ratio of 4.49, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

8 Analysts Assess Cheniere Energy: What You Need To Know

In the preceding three months, 21 analysts have released ratings for Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $300.9, a high estimate of $324.00, and a low estimate of $264.00. This upward trend is evident, with the current average reflecting a 1.35% increase from the previous average price target of $296.90.
<img src="https://www.benzinga.com/files/images/story/2025/1745960472_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Progressive. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$320.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$324.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$288.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$288.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$297.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$297.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$319.00</td>
<td>$327.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$320.00</td>
<td>$317.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$288.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$287.00</td>
<td>$267.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$287.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$300.00</td>
<td>$318.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$285.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$264.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$318.00</td>
<td>$333.00</td>
</tr>
<tr>
<td>Harry Fong</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$317.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$264.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$307.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$313.00</td>
<td>$302.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Progressive. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Progressive compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Progressive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Progressive's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PGR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Progressive analyst ratings.</a>
<h2>Get to Know Progressive Better</h2>
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 24 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
<h3>Progressive: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Progressive's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 0.66%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Progressive's net margin excels beyond industry benchmarks, reaching 12.58%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Progressive's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.36%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

21 Analysts Assess Progressive: What You Need To Know

Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $65.1, a high estimate of $80.00, and a low estimate of $45.00. This current average represents a 29.01% decrease from the previous average price target of $91.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1745960463_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Skyworks Solutions among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ruben Roy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$62.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$72.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$60.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Skyworks Solutions. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Skyworks Solutions compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Skyworks Solutions's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Skyworks Solutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SWKS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Skyworks Solutions analyst ratings.</a>
<h2>All You Need to Know About Skyworks Solutions</h2>
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
<h3>Financial Insights: Skyworks Solutions</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Skyworks Solutions's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -11.07%. This indicates a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Skyworks Solutions's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 15.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Skyworks Solutions's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.54%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Skyworks Solutions's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Skyworks Solutions's debt-to-equity ratio is below the industry average. With a ratio of 0.19, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SWKS

Forecasting The Future: 10 Analyst Projections For Skyworks Solutions

Tetra Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTI#NYSE">TTI</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 by 83.33 percent. This is a 120 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $157.14 million which missed the analyst consensus estimate of $163.85 million by 4.10 percent. This is a 4.09 percent increase over sales of $150.97 million the same period last year.

Tetra Technologies Q1 Adj. EPS $0.11 Beats $0.06 Estimate, Sales $157.14M Miss $163.85M Estimate

Press Releases

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Health Care

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Financing

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Management

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

ELTX

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Agenus

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Biomea Fusion

Climb Bio

Caribou Biosciences

CervoMed

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Seres Therapeutics

MediciNova

Sutro Biopharma

Instil Bio

Tenaya Therapeutics

Vigil Neuroscience

Vor Biopharma

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Exicure

HC Wainwright & Co.

Jones Trading

Screenshot 2024-06-07 at 5.22.00 PM

Biotech

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors

Screenshot 2024-04-10 at 5.39.01 PM

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry

Screenshot 2024-04-04 at 5.26.54 PM

Unlocking The Power Of Immunotherapy: Elicio Therapeutics&#39; (NASDAQ: ELTX) Novel AMP Platform

Comments

Elicio Therapeutics

ニュース

パートナーシップ

ベンジンガ・グローバル